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Background: Subgroup analyses from randomized controlled trials (RCT) of carotid endarterectomy (CEA) for both
symptomatic and asymptomatic carotid stenosis suggest less benefit in women compared to men, due partly to
higher age-independent peri-operative risk. However, a meta-analysis of case series and databases focussing on
CEA-related gender differences has never been investigated.
Methods: A systematic review of all available publications (including case series, databases and RCTs) reporting data
on the association between sex and procedural risk of stroke and/or death following CEA from 1980 to 2015 was
investigated. Pooled Peto odds ratios of the procedural risk of stroke and/or death were obtained by Mantel-Haenszel
random-effects meta-analysis. The I2 statistic was used as a measure of heterogeneity. Potential publication bias was
assessed with the Egger test and represented graphically with Begg funnel plots of the natural log of the OR versus its
standard error. Additional sensitivity analyses were undertaken to evaluate the potential effect of key assumptions and
study-level factors on the overall results. Meta-regression models were formed to explore potential heterogeneity as a
result of potential risk factors or confounders on outcomes. A tria sequential analysis (TSA) was performed with the aim
to maintain an over- all 5 % risk of type I error, being the standard in most meta- analyses and systematic reviews.
Results: 58 articles reported combined stroke and mortality rates within 30 days of treatment. In the unselected
overall meta-analysis, the incidence of stroke and death in the male and female groups differed significantly (Peto
OR, 1,162; 95 % CI, 1.067-1.266; P = .001), revealing a worse outcome for female patients. Moderate heterogeneity
among the studies was identified (I2 = 36 %), and the possibility of publication bias was low (P = .03). In sensitivity
analyses the meta-analysis of case series with gender aspects as a secondary outcome showed a significantly
increased risk for 30-day stroke and death in women compared to men (Peto OR, 1.390; 95 % CI, 1.148-1.684;
P = .001), In contrast, meta-analysis of databases (Peto OR, 1.025; 95 % CI, 0.958-1.097; P = .474) and case series
with gender related outcomes as a primary aim (Peto OR, 1.202; 95 % CI, 0.925-1.561; P = .168) demonstrated no
increase in operative risk of stroke and death in women compared to men.
Conclusions: Metanalyses of case series and databases dealing with CEA reveal inconsistent results regarding
gender differences related to CEA-procedure and should not be transferred into clinical practice.
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Carotid endarterectomy (CEA) has been shown to be a
more effective therapeutic option compared to the best
medical treatment alone in the prevention of ischemic
stroke, with acceptably low perioperative (30-day) stroke
and death rates [1–4]. The subgroup analyses of NASCET
(North American Symptomatic Carotid Endarterectomy
Trial), ACAS (Asymptomatic Carotid Atherosclerosis
Study), and ECST (European Carotid Surgery Trial) sug-
gested that CEA may not be as efficacious in women as it
is in men [5, 6] and that women might have higher risk of
perioperative adverse events compared to men [1, 2]. It
has been speculated, that the lower magnitude of benefit
in women was due partly to a slightly higher operative risk
in women as compared to men combined with the lower
natural history risk of stroke in women [5–7]. However, it
is not clear whether these subgroup analyses can be trans-
ferred to a non-trial setting because the CEA trials had
specific inclusion and exclusion criteria. Moreover, even
among patients who are eligible for randomisation, it is
known from other trials that there are systematic differ-
ences between patients who are recruited and those who
are not [8] and trial recruitment tends to be most selective
in women [9]. Whereas a considerable body of literature
challenges the overall benefit of CEA in unselected women
compared to men, other studies on larger CEA data-
bases suggested no substantial gender differences [10,
11]. Therefore it is crucial to determine whether the
gender related differences of operative risks in women
in the trials of CEA are also present in routine clinical
practice. Since only operative mortality, rather than the
risk of stroke and death, is recorded in the large-scale
statewide or national reports of routinely collected data
on outcome after CEA [12–15], a meta-analysis of all
available publications (including case series, databases
and RCTs) published during 1980–2015 that reported
the perioperative risk of stroke and death following
CEA by gender was performed.Methods
Information sources and search strategy
We conducted PubMed (1950 to present), EMBASE (1980
to present), and Cochrane Central Register of Controlled
Trials searches using the Medical Subject Headings
terms endarterectomy, carotid, stents, and carotid sten-
osis and combining them with key terms associated with
sex (eg, sex, gender, men, male, women, and female) and
the word risk. The last search was run in January 2015.
A secondary search consisted of manual scrutiny of the
reference lists of review articles, meta-analyses, and
original studies identified by the electronic searches to
find other eligible trials. There was no language restriction
for the search.Eligibility criteria
All published studies reporting 30-day (or similar) peri-
operative risk of stroke and/or death following CEA for
symptomatic or asymptomatic stenosis, which stratified
their results according to patient sex either as the main
objective of the study or as a substudy were considered.
Studies were included if they fulfilled the following
criteria:
1) The numbers of combined strokes and/or deaths
occurring within 30 days of CEA (or similar time
period) were reported.
2) The risks of stroke and/or death were defined, or
calculable, per operation.
3) Operative risks were reported according to sex of
the patients.
Studies were excluded if:
1) They concerned carotid surgery for non-atherosclerotic
disease.
2) They included patients undergoing bilateral
simultaneous CEA and did not report data
separately on patients undergoing unilateral
procedures.
3) They included patients undergoing synchronous
CEA and coronary artery bypass grafting and did
not report data separately on patients undergoing
CEA only.
4) They concerned the risks of surgery in a specific sex
but did not report data on the other sex.
Data collection
The data sought included (1) study characteristics (year of
publication, patient recruitment period, number of pa-
tients or procedures); (2) baseline demographic and clin-
ical characteristics of the patients (age, sex, hypertension,
diabetes mellitus, coronary artery disease, peripheral artery
disease, dyslipidemia, smoking status, and symptomatic or
asymptomatic carotid disease); (3) procedural characteris-
tics (type of anesthesia, use of shunt, and type of CEA [pri-
mary or redo CEA]); and (4) outcome parameters, as
defined above.
Quality assessment
Study quality was quantified with the Newcastle-Ottawa
Scale [16] for case–control observational studies. The
Jadad scale was applied for the assessment of RCTs [17].
Statistical analysis
Overall analyses
Meta-analyses were performed to calculate the overall
relative odds of death, and combined stroke and death
according to sex by the Mantel-Haenszel method. The
Luebke and Brunkwall BMC Cardiovascular Disorders  (2015) 15:32 Page 3 of 21Peto method for odds ratios (ORs) [18, 19] was used for
studies with few events. To counterbalance random effects
of the different studies, such as variabilities of baseline
characteristics, the summary estimates of Peto ORs was
applied. Intention-to-treat meta-analysis was performed in
line with recommendations from the Cochrane Collabor-
ation and the Preferred Reporting Items for Systematic
Reviews and Meta- analyses Statement [20] using standard
software (Comprehensive Meta-Analysis 2.0 software,
Biostat, Englewood, NJ).
Sensitivity analyses
Analyses were also performed separately for trial (RCTs)
and non-trial populations (databases and case-series)
and, among non-trial populations, for studies in which
the effect of sex on operative risk was the primary focus
(primary aim) of the study versus those where it was re-
ported as a subanalysis, usually along with other risk fac-
tors (secondary aim). Where the data were reported, the
proportions of asymptomatic patients patients amongst
females versus males were determined also. In order to
analyse those studies separately with a contemporary
and adequate best medical treatment and surgical pro-
cedure a cut-off was set for the last ten years, analysing
studies published before the year 2004 versus those pub-
lished after the year 2004. The difference between the
estimates of the subgroups was analysed according to
tests for interaction [21]. P < .05 indicates that the effects
of treatment differ between the tested subgroups.
Proof of heterogeneity and bias
Heterogeneity was assessed using the I2 statistic [22]. I2 is
the proportion of total variation observed between the tri-
als attributable to differences between trials rather than
sampling error (chance), with I2 < 25 % considered low
and I2 > 75 % considered high. Potential publication bias
(ie, bias resulting from the greater likelihood of publishing
favourable results) was assessed with the Egger test and
represented graphically with Begg funnel plots of the nat-
ural log of the OR versus its standard error [23, 24].
Meta-regression
A full meta-analysis random-effect approach to the
regression had been used, where studies are weighted by a
combination of their within-study variance and the degree
of heterogeneity. In detail, meta-regression models were
formed to explore potential heterogeneity as a result of
changes in practice over time and to evaluate the effect of
age and other risk factors or potential confounders on out-
comes (coronary artery disease, peripheral artery disease,
arterial hypertension, diabetes mellitus, dyslipidemia,
smoking status, symptom status). We used residual max-
imum likelihood to estimate the additive (between-study)
component of variance 2 for the metaregression analysis.Bootstrap analyses were performed using a Monte Carlo
permutation test for metaregression using 10 000 random
permutations [25].Trial sequential analysis
Cumulative meta-analysis of trials is at risk for produ-
cing random errors because of few data and repetitive
testing of accumulating data, and the information size
requirement analogous to the sample size of a single
optimally powered clinical trial may not be met [26, 27].
In order to quantify the risk for random errors a trial se-
quential analysis (TSA) was performed The underlying
assumption for TSA is that significance testing is per-
formed each time a new trial is published. The TSA
depends on the quantification of the required informa-
tion size. In this context, the smaller the required infor-
mation size is, the more lenient the TSA is, thus the
more lenient the criteria are for statistical significance
[26, 27]. The TSA was performed with a desire to main-
tain an over- all 5 % risk of type I error, being the stand-
ard in most meta- analyses and systematic reviews, and
we calculated the required information size (ie, the
meta-analysis information size needed to detect or reject
an intervention effect of a 20 % [or 15 %] relative risk in-
crease [RRI] with a 20 % risk of type II error and power
of 80 %) [26, 27].Results
Our literature search yielded a total of 3806 unique arti-
cles on CEA of which 58 were eligible for this review
(Fig. 1 shows the flow diagram of study selection for the
analysis), totalling 8 RCTs, 12 databases and 38 case-
series [1–3, 10, 11, 28–85]. 4 records had been excluded
because they were series from the same institutions with
duplicate clinical material. A further 6 articles had been
excluded because they were reviews, or population-
based studies from which accurate data could not be ex-
tracted. Another 3738 records were excluded because
the title or the abstract were not relevant. This left 58
studies for analysis reporting data on sex and periopera-
tive risk of CEA. The total number of CEAs included in
our analysis was 468 045, of which 188 168 (40.2 %)
were undertaken in women and the remaining 279 877
(59.8 %) CEAs were performed in male patients. Studies
reporting CEAs were published between 1988 and 2014,
whereas the patient recruitment period expanded from
1971 through 2013. The methodologic quality of the
RCTs, represented in the Jadad score, was low. Similarly,
a small proportion of the observational studies achieved
a NOS score > 6 (15 of 58 studies). Main demographic
and clinical features of the study populations are out-
lined in Table 1.
Fig. 1 Literature search strategy. Flow chart showing the strategy
used for the literature search
Luebke and Brunkwall BMC Cardiovascular Disorders  (2015) 15:32 Page 4 of 21Overall analyses
Combined 30-day stroke and mortality rate
All 58 articles reported combined stroke and mortality
rates perioperatively or within 30 days of treatment
(Fig. 2). The incidence of stroke and death in the male
and female groups was 4 609/279 877 (1.6 %) and 3 254/
188 168 (1.7 %), respectively, and this difference was
statistically significant (Peto OR, 1,162; 95 % CI, 1.067-
1.266; P = .001). Moderate heterogeneity among the
studies was identified (I2 = 36 %), and the possibility of
publication bias was low (P = .03).
30-day stroke rate
40 studies reported 30-day stroke rates in both gender
groups [3, 4, 10, 11, 29–32, 34–42, 52–54, 58–60, 62–67,
72–74, 76–80, 84–86] (Fig. 3). The overall stroke rate
within 30 days of treatment for men and women were 2
916/242 494 (1.2 %) and 2 110/163 346 (1.3 %), respect-
ively, and the difference between the groups was significant(Peto OR, 1.204; 95 % CI, 1.073-1.351; P = .002). Moderate
heterogeneity among the studies existed (I2 = 47.9 %), and
the likelihood of publication bias was low (P = .04).
Sensitivity analyses
Combined 30-day stroke and mortality rate
Case series - primary aim Among the 21 studies [29–34,
36–38, 40, 59, 62, 66, 67, 69, 72, 76, 78, 79, 84, 85] reporting
combined 30-day stroke and mortality rates as their
primary aim there was no difference in the association
between sex and the combined end-point when applying
the random-effects model (Peto OR, 1.202; 95 % CI,
0.925-1.561; P = .168).
However, when applying the fixed-effects model for the
same subset of data, there was a statistically significant
difference between the two genders regarding the com-
bined end-point 30-day mortality and stroke rate (Peto
OR, 1.299; 95 % CI, 1.089-1.548; P = .004). Moderate
heterogeneity among the studies existed (I2 = 32.9 %),
and the likelihood of publication bias was low (P = .23).
Case series - secondary aim
Among the 17 [41–52, 54–56, 77, 81] studies reporting
combined 30-day stroke and mortality rates as a subana-
lysis along with other risk factors or between case series
there was a significant difference in the association between
sex and the combined end-point, even when applying
the random-effects model (Peto OR, 1.390; 95 % CI,
1.148-1.684; P = .001).
When applying the fixed-effects model for the same
subset of data, there was a statistically significant differ-
ence between the two genders regarding the combined
end-point 30-day mortality and stroke rate (Peto OR,
1.400; 95 % CI, 1.180-1.662; P < .000), as well. Moderate
heterogeneity among the studies existed (I2 = 13.4 %),
and the likelihood of publication bias was low (P = .82).
Population based databases
Among the 12 database-studies [10, 11, 35, 39, 63–65,
73, 74, 80, 82, 83] reporting combined 30-day stroke and
mortality rates as a secondary end-point there was no
difference in the association between sex and the com-
bined end-point when applying the random-effects
model (Peto OR, 1.025; 95 % CI, 0.958-1.097; P = .474)
as well as when using the fixed-effects model (Peto OR,
1.022; 95 % CI, 0.969-1.079; P = .419). Low heterogeneity
among the studies existed (I2 = 11.2 %), and the likeli-
hood of publication bias was low (P = .83).
RCTs
Among the 10 RCTs [1–4, 56, 58, 69, 75, 86, 87] reporting
combined 30-day stroke and mortality rates as a subanaly-
sis along with other risk factors there was a significant dif-
ference in the association between sex and the combined




























Schneider 1997 [28] CS/P 155 271 0,9887 0,6535 1997 30 23 - - 74 68 16
Rigdon 1998 [29] CS/P 175 254 0,6951 0,4523 1998 - - - - - - -
Akbari 2000 [30] CS/P 520 778 −0,2442 0,3948 2000 51 44 - - 77 66 42
Ballotta 2000 [31] CS/P 196 423 −0,4899 0,8064 2000 35 35 43 46 64 55 48
Sternbach 2000 [33] CS/P 68 88 0,2612 1,4235 2000 - - 47 47 70 69 24
Schneider 2000 [32] CS/P 90 492 −0,7106 1,0508 2000 - - - - - - -
James 2001 [36] CS/P 125 199 0,4772 0,7165 2001 51 45 60 56 75 66 21
Mattos 2001 [35] CS/P 465 739 −0,9296 0,7927 2001 33 33 - - 66 61 29
Sarac 2002 [37] CS/P 1148 2274 0,4837 0,2212 2002 74 74 - - - - 23
Lane 2003 [39] CS/P 115 246 0,9757 0,6164 2003 50 58 17 29 75 70 17
Lee 2003 [83] CS/P 600 903 −0,1240 0,4020 2003 48 45 45 37 77 67 41
Weise 2004 [84] CS/P 56 156 0,5953 0,5927 2004 27 26 37 34 70 57 29
Harthun 2005 [78] CS/P 5950 8144 0,3474 0,1381 2005 - - - - 77 77 8
Hugl 2006 [77] CS/P 115 229 −2,6675 1,4444 2006 84 76 - - - - -
Park 2008 [75] CS/P 40 53 −1,3691 1,5633 2008 52 53 - - 93 94 30
Dorigo 2009 [71] CS/P 1200 2809 0,8562 0,4097 2009 66 64 32 27 73 64 22
Poisson 2010 [65] CS/P 52 84 −1,1718 1,1100 2010 69 61 44 53 72 71 25
Yavas 2010 [66] CS/P 42 163 −0,7495 1,0751 2010 38 35 41 22 52 41 21
Baracchini 2012 [61] CS/P 466 992 0,2461 0,7324 2012 32 36 60 52 66 59 29
Luebke 2014 [58] CS/P 588 1292 0,095 0,4113 2013 78 75 33 39 85 81 22
Guzman 2013 [59] CS/P 363 683 −0,1327 0,4624 2013 33 36 50 52 76 72 23
Friedmann 1988 [40] CS/S 280 408 −0,1776 0,3870 1988 - - - - - - -
Maxwell 1990 [42] CS/S 289 345 0,8866 0,6176 1990 - - - - - - -
Magnan 1993 [43] CS/S 90 300 0,1837 0,5354 1993 - - - - - - -
Goldstein 1994 [44] CS/S 256 441 −0,054 0,2840 1994 - - - - - - -
Riles 1994 [41] CS/S 844 1488 0,2052 0,2541 1994 - - - - - - -
Plestis 1996 [45] CS/S 396 610 0,8950 0,4322 1996 - - - - - - -
Hertzer 1997 [46] CS/S 652 1272 0,6340 0,3162 1997 60 60 - - - - -
Kerdiles 1997 [47] CS/S 103 178 −0,3499 0,4409 1997 - - - - - - -
Goldstein II 1998 [80] CS/S 151 312 1,2340 0,5790 1998 - - - - - - -














Table 1 Baseline characteristics of included studies (Continued)
Kucey 1998 [48] CS/S 434 847 0,3147 0,2342 1998 - - - - - - -
Blohme 1999 [50] CS/S 94 178 −0,4864 0,5920 1999 - - - - - - -
Hartmann 1999 [51] CS/S 46 62 0,5700 0,7011 1999 - - - - - - -
Frawley 2000 [53] CS/S 312 688 0,3915 0,5315 2000 5 5 - - - - -
Naylor 2000 [54] CS/S 171 329 0,4833 0,6130 2000 - - - - - - -
Eckstein 2002 [55] CS/S 45 119 −0,5647 0,8021 2002 - - - - - - -
Dalainas 2007 [76] CS/S 936 2396 0,5283 0,1894 2007 29 70 - - - - -
McCrory 1993 [82] DB 407 753 0,055 0,2411 1993 - - - - - - -
Huber 1998 [81] DB 19508 27233 0,095 0,067 1998 - - - - - - -
Rockman 2001 [34] DB 991 1485 −0,3863 0,5409 2001 34 30 - - 62 54 20
Tu 2003 [79] DB 2096 3942 0,038 0,1127 2003 - 31 - - - 64 -
Kapral 2003 [38] DB 2096 3942 0,060 0,1131 2003 31 30 37 35 71 61 23
Sidawy 2009 [72] DB 551 817 −0,2644 0,1156 2009 40 60 - - - - -
Halm 2009 (198–1999) [73] DB 4125 5181 0,1419 0,1061 2009 - - - - - - -
Rockman 2011 [64] DB 21621 29162 −0,037 0,5856 2011 95 95 - - - - -
Bisdas NYS 2012 [62] DB 1969 3133 0,0676 0,1908 2012 92 91 45 44 74 71 29
Menyhei 2012 [63] DB 15358 32637 0,7540 0,5774 2012 32 68 - - - - -
Jim 2013 [11] DB 2678 3814 0,0241 0,1390 2013 61 58 - - 85 83 31
Kuy 2014 (NIS DATABASE) [10] DB 94404 126849 0,008 0,036 2014 91 90 - - - - -
ACAS 1995 [1] RCT 281 544 0,7855 0,4654 1995 - - - - - - -
ECST 1998 [3] RCT 842 1962 0,5210 0,1932 1998 - - - - - - -
NASCET 1998 [4] RCT 424 1012 0,1660 0,2513 1998 - - - - - - -
ACE 1999 [57] RCT 842 1962 0,2067 0,1848 1999 - - - - - - -
ACST 2004 [2] RCT 469 936 0,4007 0,3249 2004 - - - - - - -
CAVATAS 2009 [74] RCT 75 178 −0,3873 0,3633 2009 - - - - - - -
EVA-3 s, SPACE, ICSS [56, 69,
87, 98]
RCT 476 1232 0,2746 0,2203 2010 - - - - - - -























































Schneider 1997 [28] 22 - - 39 53 59 58 72 71 28 28 - -
Rigdon 1998 [29] - - - - - - - - - - - - -
Akbari 2000 [30] 36 - - 40 50 53 68 71 70 - - - -
Ballotta 2000 [31] 30 61 69 17 24 71 62 71 70 13 15 - -
Sternbach 2000 [33] 19 - - 13 29 47 60 71 70 - - - -
Schneider 2000 [32] - - - – - - - - - - - - -
James 2001 [36] 21 - - 10 15 68 74 70 70 71 71 - -
Mattos 2001 [35] 23 - - 27 39 41 51 69 68 61 61 - -
Sarac 2002 [37] 22 - - 57 73 - - 69 69 - - 7 6
Lane 2003 [39] 25 - - 10 8 58 68 73 71 33 30 - -
Lee 2003 [83] 36 17 18 40 50 69 84 71 70 79 74 - -
Weise 2004 [84] 25 18 19 23 22 - - 65 64 - - - -
Harthun 2005 [78] 6 - - 28 40 - - 70 70 - - - -
Hugl 2006 [77] - - - - - - - - - - - - -
Park 2008 [75] 23 - - 23 17 70 70 70 72 - - - -
Dorigo 2009 [71] 19 25 34 15 23 36 81 72 71 - - 3 4
Poisson 2010 [65] 42 10 10 27 40 77 91 76 73 - - - -
Yavas 2010 [66] 22 14 31 15 19 12 34 64 65 69 70 - -
Baracchini 2012 [61] 34 53 60 40 45 63 69 76 75 18 14 - -
Luebke 2014 [58] 26 24 30 34 45 32 38 76 75 24 17 - -
Guzman 2013 [59] 25 25 32 38 47 62 68 71 70 82 79 2 1
Friedmann 1988 [40] - - - - - - - - - - - - -
Maxwell 1990 [42] - - - - - - - - - - - - -
Magnan 1993 [43] - - - - - - - - - - - - -
Goldstein 1994 [44] - - - - - - - - - - - - -
Riles 1994 [41] - - - - - - - - - - - - -
Plestis 1996 [45] - - - - - - - - - - - - -
Hertzer 1997 [46] - - - - - - - - - - - - -
Kerdiles 1997 [47] - - - - - - - - - - - - -
Goldstein II 1998 [80] - - - - - - - - - - - - -














Table 1 Baseline characteristics of included studies (Continued)
Kucey 1998 [48] - - - - - - - - - - - - -
Blohme 1999 [50] - - - - - - - - - - - - -
Hartmann 1999 [51] - - - - - - - - - - - - -
Frawley 2000 [53] - - - - - - - 68 68 - - - -
Naylor 2000 [54] - - - - - - - - - - - - -
Eckstein 2002 [55] - - - - - - - - - - – - -
Dalainas 2007 [76] - - - - - - - - - - - - -
McCrory 1993 [82] - - - - - - - - - - - - -
Huber 1998 [81] - - - - - - - - - - - - -
Rockman 2001 [34] 23 - - 38 50 36 38 69 69 31 30 - -
Tu 2003 [79] 23 - 27 - 36 - 43 - - - - - -
Kapral 2003 [38] 23 25 28 33 37 63 76 68 68 29 29 - -
Sidawy 2009 [72] - - - - - - – - - - - - -
Halm 2009 (198–1999) [73] - - - - - - - - - - - - -
Rockman 2011 [64] - - - - - - - - - - - - Blank
Bisdas NYS 2012 [62] 29 - - 34 45 - - 72 71 - - - -
Menyhei 2012 [63] - - - - - - - - - - - - -
Jim 2013 [11] 32 45 42 40 54 57 63 71 71 - - 10 8
Kuy 2014 (NIS DATABASE) [10] - - - - - - - - - - - - -
ACAS 1995 [1] - - - - - - - - - - - - -
ECST 1998 [3] - - - - - - - - - - - - -
NASCET 1998 [4] - - - - - - - - - - - - -
ACE 1999 [57] - - - - - - - - - - - - -
ACST 2004 [2] - - - - - - - - - - - - -
CAVATAS 2009 [74] - - - - - - - - - - - - -
EVA-3 s, SPACE, ICSS [56, 69, 87, 98] - - - - - - - - - - - - -














Fig. 2 Forrest plot for carotid endarterectomy and stroke and death rates subjected to the gender. The odds for stroke and death within 30 days
of CEA for females versus males. P is the statistical significance of the pooled Peto odds ratio. The size of the data marker indicates the weight of
each trial. OR, odds ratio
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Fig. 3 Forrest plot for carotid endarterectomy and stroke rates subjected to the gender. The odds for stroke within 30 days of CEA for females
versus males. P is the statistical significance of the pooled Peto odds ratio. The size of the data marker indicates the weight of each trial. OR,
odds ratio
Luebke and Brunkwall BMC Cardiovascular Disorders  (2015) 15:32 Page 10 of 21
Luebke and Brunkwall BMC Cardiovascular Disorders  (2015) 15:32 Page 11 of 21end-point, even when applying the random-effects model
(Peto OR, 1.302; 95 % CI, 1.060-1.600; P = .012).
When applying the fixed-effects model for the same
subset of data, there was a statistically significant differ-
ence between the two genders regarding the combined
end-point 30-day mortality and stroke rate (Peto OR,
1.310; 95 % CI, 1.089-1.576; P = .004), as well. Low het-
erogeneity among the studies existed (I2 = 15 %), and the
likelihood of publication bias was low (P = .69).
All study types with gender analyses as a secondary aim
When combining all 38 [1–4, 10, 11, 35, 39, 41–52, 54–56,
58, 63–65, 69, 73–75, 77, 80–83, 86, 87] studies with
gender analyses as a secondary aim, random-effects meta-
analysis as well as fixed-effects meta-analysis reveal a
significant association between sex and the combined end-
point (Peto OR, 1.150; 95 % CI, 1.050-1.260; P = .003 and
Peto OR, 1.068; 95 % CI, 1.017-1.123; P = .009, respect-
ively). Moderate heterogeneity among the studies existed
(I2 = 36.1 %), and the likelihood of publication bias was
low (P = .61).
Studies published after the year 2004
Among the 24 studies [2, 10, 11, 56, 59, 60, 62–67, 69,
72–79, 85–87] published after the year 2004 and report-
ing combined 30-day stroke and mortality rates there
was no difference in the association between sex and the
combined end-point when applying the random-effects
model (Peto OR, 1.119; 95 % CI, 0.983-1.274; P = .088)
as well as when using the fixed-effects model (Peto OR,
1.043; 95 % CI, 0.984-1.105; P = .155). Moderate hetero-
geneity among the studies existed (I2 = 45.5 %), and the
likelihood of publication bias was low (P = .38).
The combined outcome estimate of combined 30-day
mortality and stroke rates was not substantially affected
when the primary analysis was repeated with a fixed-
effects model (OR, 1.084; 95 % CI, 1.033-1.137; P = .001),
altered data sets after excluding each single study at a time
(OR, 1.177; 95 % CI, 1.076-1.297; P < .01), or cumulative
analysis (OR, 1.177; 95 % CI, 1.076-1.2879; P < .01).
30-day stroke rate
Case series - primary aim
Among the 20 [29–32, 34, 36–38, 40, 59, 60, 62, 66, 67,
72, 76, 78, 79, 84, 85] studies reporting 30-day stroke
rates as their primary aim there was no difference in the
association between sex and the end-point when apply-
ing the random-effects model (Peto OR, 1.322; 95 % CI,
0.922-1.895; P = .129).
However, when applying the fixed-effects model for
the same subset of data, there was a statistically signifi-
cant difference between the two genders regarding the
end-point 30-day stroke rate (Peto OR, 1.235; 95 % CI,
1.024-1.490; P = .027). Moderate heterogeneity amongthe studies existed (I2 = 63.4 %), and the likelihood of
publication bias was low (P = .44).
Case series - secondary aim
Among the 6 studies [41, 42, 52–54, 77] reporting 30-day
stroke rates as a subanalysis along with other risk factors
or between case series there was a significant difference
in the association between sex and the end-point, even
when applying the random-effects model (Peto OR, 1.403;
95 % CI, 1.052-1.871; P = .021).
When applying the fixed-effects model for the same
subset of data, there was a statistically significant differ-
ence between the two genders regarding the end-point
30-day stroke rate (Peto OR, 1.403; 95 % CI, 1.052-1.871;
P = .021), as well. No heterogeneity among the studies
existed (I2 = 0 %), and the likelihood of publication bias
was low (P = .71).
Population based databases
Among the 10 database-studies [10, 11, 35, 39, 63–65,
73, 74, 80] reporting 30-day stroke rates as a secondary
end-point there was no difference in the association be-
tween sex and the end-point when applying the random-
effects model (Peto OR, 1.060; 95 % CI, 0.992-1.133;
P = .086) as well as when using the fixed-effects model
(Peto OR, 1.060; 95 % CI, 0.992-1.133; P = .086). No het-
erogeneity among the studies existed (I2 = 0 %), and the
likelihood of publication bias was low (P = .12).
RCTs
Among the 4 RCTs [3, 4, 58, 86] reporting 30-day stroke
rates as a subanalysis along with other risk factors there
was no difference in the association between sex and the
end-point, even when applying the random-effects model
(Peto OR, 1.364; 95 % CI, 0.979-1.901; P = .067).
However, when applying the fixed-effects model for
the same subset of data, there was a statistically signifi-
cant difference between the two genders regarding the
end-point 30-day stroke rate (Peto OR, 1.398; 95 % CI,
1.106-1.765; P = .005), as well. Moderate heterogeneity
among the studies existed (I2 = 45.8 %), and the likeli-
hood of publication bias was low (P = .73).
All study types with gender analyses as a secondary aim
When combining all 20 studies [3, 4, 10, 11, 35, 39, 41, 42,
52–54, 58, 63–65, 73, 74, 77, 80, 86] with gender analyses
as a secondary aim, random-effects meta-analysis as well
as fixed-effects meta-analysis reveal a significant associ-
ation between sex and the end-point (Peto OR, 1.140;
95 % CI, 1.040-1.249; P = .005 and Peto OR, 1.096; 95 %
CI, 1.029-1.167; P = .004, respectively). Low heterogeneity
among the studies existed (I2 = 18.9 %), but the likelihood
of publication bias was high (P = .02).
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Among the 19 studies [10, 11, 59, 60, 62–67, 72–74,
76–79, 85, 86] published after the year 2004 and
reporting 30-day stroke rates there was no difference in
the association between sex and the end-point when ap-
plying the random-effects model (Peto OR, 1.182; 95 %
CI, 0.989-1.414; P = .066). However, when using the fixed-
effects model (Peto OR, 1.071; 95 % CI, 1.002-1.144;
P = .043) a significant difference was revealed. Moderate
heterogeneity among the studies existed (I2 = 65.4 %), and
the likelihood of publication bias was low (P = .21).
The combined outcome estimate of combined 30-day
mortality and stroke rates was not substantially affected
when the primary analysis was repeated with a fixed-
effects model (OR, 1.109; 95 % CI, 1.045-1.177; P = .001),
altered data sets after excluding each single study at a time
(OR, 1.216; 95 % CI, 1.077-1.373; P = .002), or cumulative
analysis (OR, 1.216; 95 % CI, 1.077-1.373; P = .002).Meta-regression analyses
Meta-regression analysis investigated potential effects of
clinical confounders on perioperative adverse events as-
sociated with CEA subjected to the gender.Year of publication
Random-effects meta- regression revealed a statistical sig-
nificant evidence for an association between the log OR
for 30-day stroke and mortality and the year of publication
(p = .004) (Fig. 4). This underlines that stroke and mortality



























Fig. 4 Scatterplot of the relationship between year of publication and Log
between year of publication and log odds ratio for stroke and mortalityassociation (slope coefficient (s.e.) = −0.01105 (0,00344),
p = .00127).
Mean age
Details on mean age were available in 24 studies (avail-
ability of information: 60 832/468 045 patients, 12.9 %).
Metaregression showed no statistically significant associ-
ation between mean age and 30-day stroke and mortality
(slope coefficient (s.e.) = 0.00972 (0.03199), p = .532).
Arteria hypertension
Details on arterial hypertension were available in 23 stud-
ies (availability of information: 54 314/468 045 patients,
11.6 %). Metaregression showed no statistically significant
association between arterial hypertension and 30-day
stroke and mortality (slope coefficient (s.e.) = 0.00310
(0.00661), p = .582).
Diabetes mellitus
Details on diabetes mellitus were available in 24 studies
(availability of information: 57 736/468 045 patients,
12.3 %). Metaregression showed no statistically signifi-
cant association between diabetes mellitus and 30-day
stroke and mortality (slope coefficient (s.e.) = −0.01472
(0.00655), p = 0.482).
Coronary artery disease
Details on coronary artery disease were available in 24
studies (availability of information:56 496/468 045 pa-
tients, 12.1 %). Metaregression documented no statisti-
cally significant association between coronary arteryr on Log Peto odds ratio
ation year
01,00 2004,12 2007,24 2010,36 2013,48 2016,60
Odds Ratio for stroke and death. Scatterplot shows the relationship
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(s.e.) = −0.00134 (0.00512), p = 0.445).
Peripheral arterial disease
Details on peripheral artery disease were available in 12
studies (availability of information:27 540/468 045 pa-
tients, 5.9 %). Metaregression documented no statisti-
cally significant association between coronary artery
disease and 30-day stroke and mortality (slope coefficient
(s.e.) = −0.00313 (0.00932), p = 0.726).
Dyslipidemia
Details on dyslipidemia were available in 15 studies
(availability of information: 24 289/468 045 patients,
5.2 %). Metaregression showed no statistically significant
association between dyslipidemia and 30-day stroke and
mortality (slope coefficient (s.e.) = −0.00691 (0.00735),
p = 0.801).
Smoking status
Details on smoking status were available in 20 studies
(availability of information: 34 906/468 045 patients,
7.4 %). Metaregression showed no statistically signifi-
cant association between smoking status and 30-day
stroke and mortality (slope coefficient (s.e.) = 0.00593
(0.00579), p = 0.677).
Symptom status
Details on symptom status were available in 30 studies
(availability of information: 371 485/468 045 patients,
79.4 %). Metaregression showed a statistically signifi-
cant association between symptom status and 30-day
stroke and mortality (slope coefficient (s.e.) = −0.00049
(0.00153), p = 0.00893).
Quality assessment
The methodologic quality of the 10 RCTs included in
the present meta-analysis, represented in the Jadad
score, was low (all studies: Jadad score 3). Similarly, only
a small proportion of the observational studies achieved
a NOS score > 6 (15 of 58 studies).
TSA for 30-day stroke and mortality rate
For the outcome of 30-day death or stroke, the required
diversity was calculated based on an RRI of 20 %, alpha
of 5 %, and beta of 20 %.
Studies published after the year 2004
The cumulative z curve crossed both the traditional
boundary and the TSMB for the outcomes of death or
stroke, demonstrating firm evidence for a 20 % RRI in
the female group compared with the male group (Fig. 5).Case series – primary aim
The cumulative z curve crossed the traditional boundary
but not the TSMB, suggesting a lack of firm evidence for
an RRI of 20 % in the female group compared with the
male group (Fig. 6).
Case series – secondary aim
The cumulative z curve crossed the traditional boundary
but not the TSMB, suggesting a lack of firm evidence for
an RRI of 20 % in the female group compared with the
male group (Fig. 7).
RCTs
The cumulative z curve crossed the traditional boundary
but not the TSMB, suggesting a lack of firm evidence for
an RRI of 20 % in the female group compared with the
male group.
Discussion
Gender-based outcomes and the etiology of sex-related
mechanisms in patients treated with CEA are a topic of
considerable debate in the recent vascular literature [34,
35, 38, 39, 64, 71, 77, 88]. Till now, there are no gener-
ally accepted and obliging guidelines regarding the pre-
operative selection of CEA patients subjected to the
gender [59, 89, 90].
RCT data
Subgroup analysis of the large CEA-randomised trials
have suggested that the benefit from CEA would be less
in women compared to men for both, symptomatic and
asymptomatic carotid stenosis. In particular, in the
European Carotid Surgery Trial (ECST) and the
Asymptomatic Carotid Surgery Trial (ACST) women
appeared to have higher risks of perioperative compli-
cations, and in the moderate (50 % to 69 %) stenosis
arm of the North American Symptomatic Carotid End-
arterectomy Trial (NASCET) women did not appear to
benefit from surgery at all. In this subset of female
patients CEA was associated with a marginal or re-
duced long-term benefit combined with at least 2-fold
increase in the perioperative complication rate as com-
pared to men. It has been hypothesized, that the lower
degree of benefit in women was caused partly by a
(slightly) higher operative risk in combination with a
lower natural history risk of stroke in women as com-
pared to men [5–7]. However, these assumptions are
based on post-hoc subgroup analyses on results of
these RCTs and have therefore some inherent limita-
tions. Women comprised only a third of patients in
these trials (between 28 and 34 %) and this relatively
small sample size has left them underpowered to detect
important differences between women and men. In
addition to that, selection criteria for these randomized
Fig. 5 Trial sequential analysis of the effects of carotid endarterectomy on periprocedural stroke and death subjected to the gender and
publication date after the year 2004
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ings and thus limiting their generalizability to the typical
endarterectomy population. As a result, these gender-
related results are difficult to interpret due to significant
design limitations [5] and due to a lack of adjustment
for other important prognostic factors. In the recently
published International Carotid Stenting Study (ICSS),
women had a higher 120-day event rate for CEA compared
to men (7.6 % vs 4.2 %) [91]. On the contrary, in the Ca-
rotid Revascularization Endarterectomy vs Stenting Trial
(CREST), women undergoing CEA had a lower periproce-
dural event rate compared to men (3.8 % vs 4.9 %) [87].
The present unselected meta-analysis of RCTs revealed
that female patients undergoing CEA had a higher com-
bined risk of death and stroke after the intervention than
did male patients (Peto OR, 1,162; 95 % CI, 1.067-1.266;
P = .001). We analyzed the robustness of the observed
outcomes by performing sensitivity analyses. Low het-
erogeneity among the studies existed (I2 = 15 %), and the
likelihood of publication bias was low (P = .69). In the
TSA, the cumulative z curve crossed the traditional
boundary but not the TSMB, suggesting a lack of firm
evidence for an RRI of 20 % in the female group com-
pared with the male group in RCTs for the endpoint
under investigation. As a result, the higher perioperativerisk of stroke and death after CEA in women observed
in large RCTs is likely to be a statistical artifact due to
small female patient numbers. In addition to that, be-
cause of low absolute difference between the gender
related outcomes (Peto OR, 1,162; 95 % CI, 1.067-1.266;
P = .001), the clinical significance of this finding is un-
clear. As well, we found a significant difference in overall
perioperative stroke rates for CEA when men were com-
pared with women (Peto OR, 1.204; 95 % CI, 1.073-
1.351; P = .002). Sensitivity analysis revealed that there
might be a statistically significant difference between the
two genders regarding the end-point 30-day stroke rate
by using the fixed-effects model, as well (Peto OR, 1.398;
95 % CI, 1.106-1.765; P = .005), but again the clinical sig-
nificance of this small difference may be narrow. In this
sensitivity analysis, even moderate heterogeneity among
the studies existed (I2 = 45.8 %) but the likelihood of
publication bias was low (P = .73).
It has also been suggested that the RCT results may be
confounded by referral bias [86]. Women are less likely
than men to be selected for both, cardiac and peripheral
vascular surgery [92] and recent studies have demon-
strated that women are less likely to receive CEA or
angioplasty than men in the same situation [86]. There-
fore, it might be possible that those women who actually
Fig. 6 Trial sequential analysis of the effects of carotid endarterectomy on periprocedural stroke and death subjected to the gender and type of
study (outcome of interest as primary aim)
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those who do not. As a result, it is unclear whether these
RCT results can be generalised to the non-trial setting
[93, 94]. It is therefore essential to analyze whether the
RCT results of CEA are also seen in routine clinical
practice.
Non-RCT data
Sex related differences as a primary aim of the study
The case series reporting combined 30-day stroke and
mortality rates subjected to the sex as their primary aim
found CEA as safe and beneficial in women as in men
when applying the random-effects model (Peto OR,
1.202; 95 % CI, 0.925-1.561; P = .168). However, when
applying the fixed-effects model for the same subset of
data, there was a statistically significant difference be-
tween the two genders regarding the combined end-
point 30-day mortality and stroke rate (Peto OR, 1.299;
95 % CI, 1.089-1.548; P = .004). Moderate heterogeneity
among the studies existed (I2 = 32.9 %), and the likeli-
hood of publication bias was low (P = .23). However, in
TSA the cumulative z curve crossed the traditional
boundary but not the TSMB, suggesting a lack of firm evi-
dence for an RRI of 20 % in the female group compared
with the male group in case series for the endpoint underinvestigation and gender differences as their primary aim.
Thus, although those studies have shown no difference in
perioperative stroke and mortality between men and
women in the random effects model, criticism may be
pointed to the size and power of those studies, raising the
possibility of a type II error as demonstrated by TSA. The
same was true when analyzing the endpoint 30-day stroke
in case series with sex-related differences as a primary
aim, with no difference in the association between sex and
the end-point when applying the random-effects model
(Peto OR, 1.322; 95 % CI, 0.922-1.895; P = .129), but a
statistically significant difference between the two genders
regarding the end-point 30-day stroke rate when applying
the fixed-effects model (Peto OR, 1.235; 95 % CI, 1.024-
1.490; P = .027). Moderate heterogeneity among the stud-
ies existed (I2 = 63.4 %), and the likelihood of publication
bias was low (P = .44).
Sex-related differences as a secondary aim of the study
The case series reporting combined 30-day stroke and
mortality rates subjected to the gender as a secondary
aim suggest that CEA is associated with significantly in-
creased risk for periprocedural death and stroke in women
when compared with men when applying the random-
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Fig. 7 Trial sequential analysis of the effects of carotid endarterectomy on periprocedural stroke and death subjected to the gender and type of
study (outcome of interest as secondary aim)
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OR, 1.400; 95 % CI, 1.180-1.662; P < .000, respectively).
Moderate heterogeneity among the studies existed (I2 =
13.4 %), and the likelihood of publication bias was low
(P = .82). However, the cumulative z curve crossed the
traditional boundary but not the TSMB, suggesting a
lack of firm evidence for an RRI of 20 % in the female
group compared with the male group in case series for
the endpoint under investigation and gender differ-
ences as a secondary aim. Thus, although those studies
have shown a difference in perioperative stroke and
mortality between men and women in the random-
effects and the fixed effects model, criticism may be
pointed to the size and power of those studies, raising
the possibility of a type II error as demonstrated by
TSA. The same was true when analyzing the endpoint
30-day stroke in case series with gender differences as a
secondary aim, with a significant difference in the asso-
ciation between sex and the end-point when applying
the random-effects model (Peto OR, 1.403; 95 % CI,
1.052-1.871; P = .021) and the fixed-effects model (Peto
OR, 1.403; 95 % CI, 1.052-1.871; P = .021), as well. No
heterogeneity among the studies existed (I2 = 0 %), and
the likelihood of publication bias was low (P = .71).Databases
We found no difference in overall perioperative stroke
rates and combined death and stroke rates for CEA
when men were compared with women in database ana-
lyses. In extensive sensitivity analyses, we demonstrated
the robustness of all observed outcomes under investiga-
tion. Low heterogeneity among the studies existed, and
the likelihood of publication bias was low for all compar-
isons. Although registries and state-wide databases lack
the granular details of patient demographics, comorbidi-
ties and procedure preferences, they represent large di-
verse populations without the institutional selection bias.
Therefore, presumably, these databases reflect routine
real-world medical practice as compared to databases
from randomised controlled trials that usually include
tertiary care and university centres only with carefully
defined patient selection criteria and practitioner cre-
dentialing. These findings probably suggest that medical,
daily, population wide practice is rather different from
that in large centres.
Metaregression
Meta-regression analysis investigated potential effects of
publication date of each study, age, hypertension, diabetes
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dyslipidemia, smoking status, and symptomatic or asymp-
tomatic carotid disease on perioperative adverse events as-
sociated with CEA subjected to the gender. An interesting
finding of the meta-regression analysis is that only the cat-
egory “year of publication” and “symptom status” were
significant confounders for the log odds ratio for stroke
and mortality in male and female CEA patients. This es-
sentially means that in older studies, the difference in
stroke or mortality is large, becoming less as the years
pass, and this reduction in difference is statistically signifi-
cant. These results are in concordance with the study by
Rockman et al. [64]. When stratified by the presence of
preoperative symptoms, asymptomatic male and female
patients undergoing carotid intervention had a nearly
identical rate of postoperative stroke and in-hospital death.
However, symptomatic women undergoing carotid artery
interventions had a significantly higher rate of postopera-
tive stroke than symptomatic men (3.8 % vs 2.3 %, P = .03).
The clinical significance of this finding is unclear. It is pos-
sible, of course, that symptomatic female patients would be
at a higher risk for future stroke if no intervention were
performed and still benefit from intervention vs medical
management.
Own results
A former meta-analysis of the existing literature per-
formed in 2005 by Bond et al. [95] found that women
undergoing CEA did have a higher rate of operative
stroke and death than men (odds ratio, 1.31; 95 % confi-
dence interval, 1.17-1.47, P < .001). In the present meta-
analysis, the effect of sex on the operative risk of CEA in
case series was consistent with those observed in the
RCTs. Given the potential concerns about the generalis-
ability of observations made in trials to routine clinical
practice, it was important to determine whether the in-
creased operative risk of stroke and death in women ob-
served in the trials of CEA were likely to be seen in
routine clinical practice. In contrast to the results pre-
sented by Bond et al. [95], we have shown that the ef-
fects of sex on the operative risk of CEA in published
series from routine clinical practice are not consistent
with those observed in the RCTs and even differ be-
tween cases series with gender considerations as primary
aim and those with gender aspects as a secondary aim
and database analyses. Whereas the unselected overall
meta-analysis, and the meta-analysis of case series with
gender aspects as a secondary outcome showed a signifi-
cantly increased risk for 30-day stroke and death in
women compared to men, meta-analysis of databases
and case series with sex-related outcomes as a primary
aim demonstrated no increase in operative risk of stroke
and death in women compared to men. As a result, the
findings of reports in which the gender association wasthe primary subject of study were highly consistent with
those in large databases in which the gender observa-
tions was one of many associations reported. Our unse-
lected analysis found significant differences in overall
stroke and mortality outcomes between women and
men after CEA. In addition, there were also a differences
found in stroke and mortality among asymptomatic and
symptomatic patients from both sexes. These results do
not support the generalisability of the analyses of the
overall effects of CEA from the unselected study data to
routine clinical practice.
Over the decades 1980 and 2015 optimal medical treat-
ment has been changed tremendously. There is moderate
strength of evidence among three quality-A randomized
controlled trials (RCTs) (the Veterans Affairs Cooperative
Study [VA], the Asymptomatic Carotid Atherosclerosis
Study (ACAS), and the Asymptomatic Carotid Athero-
sclerosis Trial [ACST]) that carotid endarterectomy (CEA)
and best medical therapy (BMT) can reduce the risk of
ipsilateral stroke as compared with best medical therapy
alone, which was demonstrated by all three trials. How-
ever, the results from these trials are not applicable to
contemporary clinical practice, as they do not compare
CEA with contemporary best medical therapy and under
conditions of real-world adherence and persistence, re-
spectively. Surgeons in contemporary clinical trials with
up-to-date best medical treatment have also achieved
CEA periprocedural death and stroke rates lower than
those in pivotal trials. For example, in the Carotid Revas-
cularization Endarterectomy vs. Stenting Trial (CREST),
the death/stroke rates for symptomatic patients was 3.2 %
and for asymptomatic patients was 1.4 %. To date, there is
no RCT that has analysed the impact of contemporary
best medical treaetment of carotid artery stenosis sub-
jected to the sex as a primary aim of the study.
In the present study, among the 24 studies [2, 10, 11,
56, 59, 60, 62–67, 69, 72–79, 85–87] published after the
year 2004 with a contemporary best medical treatment
and reporting combined 30-day stroke and mortality
rates there was no difference in the association between
sex and the combined end-point when applying the
random-effects model as well as when using the fixed-
effects model. In addition to that, TSA showed that
confidence can be put into these results. Although, the
studies published after the year 2004 represent a more
contemporary management of patients with carotid ar-
tery stenosis, the interpretation of these results regarding
the impact of best medical treatment alone on these sex-
stratified outcomes should be done with caution.
Possible reasons for gender differences
The reasons for the postulated perioperative risk differ-
ence remain speculative and the overall evidence for out-
come differences by sex-specific characteristics is limited
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risks in women include the older age of onset of cerebro-
vascular disease in women [96]. Other explanations for
the sex disparities in benefit from CEA may be attributed
to further reasons listed in Table 2 [97–105].
Limitations
Although we believe that our results are likely to be
valid, our study does have some potential shortcomings.
First, the studies included in the review were of varying
methodological quality. Some were retrospective and only
a minority of the remainder had independent assessment
of outcome by a neurologist. However, although the abso-
lute operative risk will therefore have been underesti-
mated in some studies, this should not have biased the
within-study relative odds of stroke and death due to
surgery by sex. However, the reliability of the meta-
analyses of the within-study comparisons is supported
by the consistent results, with very little statistical het-
erogeneity between studies, in the present review. The
same argument applies to the fact that the use of ancil-
lary treatments, such as the use of patching, shunting
or local anaesthetic, will also have varied between stud-
ies. Secondly, publication bias is a potential problem
with analyses of published data. It is possible that some
of the studies looked at the interaction of several risk
factors with operative risk, but only published those
that were ‘interesting’ or statistically significant. How-
ever, funnel plots did not show any obvious skewing
suggestive of publication bias (data not shown) and the
lack of heterogeneity between studies indicates thatTable 2 Possible reasons for gender differences for carotid endarter
Possible reasons for gender differences
Epidemiology
Older age of onset of cerebrovascular disease in women
Plaque
characteristics
Higher rates of carotid artery stenosis,
Lower and more stable plaque burden for the same degre
Anatomy
Female carotid arteries are higher- velocity vessels with in
Women tend to have atherosclerotic plaque relatively loca
opposed to the proximal internal carotid artery, usually se
Smaller ICA size in women that might in turn lead to a hig
postoperative microembolization) and late (recurrent sten
Surgery
Higher surgical risk in women
Pathophysiology
Lower cerebrovascular reserves in women, as cerebrovasc
impaired in postmenopausal women compared with menselective reporting of extreme results (either associa-
tions with low operative risk or high operative risk) was
uncommon. Adequate power is difficult to achieve in
institutional or even multicenter studies to make mean-
ingful comparisons of rare events, but our analysis has
an advantage in that a large patient cohort was used to
calculate pooled outcome estimates, such as mortality
and stroke. As in other meta-analyses, given the lack of
data in each trial, we did not adjust our analyses for
medications used during and following the procedure.
Although detailed sensitivity analyses on many vari-
ables were undertaken, given heterogeneity in the study
protocols, clinically relevant differences could have
been missed and are best assessed in a meta-analysis of
individual patient data. The subgroup analyses might
suffer from multiple testing. As a result, the results of
the sensitivity analyses are best described as secondary
and hypothesis generating only. In addition to that, our
report is limited by the heterogeneous groups of pa-
tients entering the meta- analysis models. No adjust-
ments for differences in clinical characteristics of the
study populations, such as presenting symptom status
and atherosclerotic comorbidity, could be made. Fur-
ther more, each of these studies reported the results of
operations performed by multiple surgeons and, in the
latter case, in multiple institutions. As a result, there
was no standardization of the surgical approach with
respect to the method of anesthesia, the use and
method of cerebral monitoring, the use of an indwell-
ing shunt, closure of the arteriotomy with a patch, and
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ular reactivity after hypercapnia was found to be more
of the same age
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analysis of the impact of gender on surgical outcome.
Conclusions
In conclusion, we have shown that the effects of sex on
the operative risk of CEA in published series from rou-
tine clinical practice are not consistent with those ob-
served in the RCTs and even differ between cases series
with gender considerations as primary aim and those
with gender aspects as a secondary aim and database
analyses. Whereas the unselected overall meta-analysis,
and the meta-analysis of case series with gender aspects
as a secondary outcome showed a significantly increased
risk for 30-day stroke and death in women compared to
men, meta-analysis of databases and case series with
gender related outcomes as a primary aim demonstrated
no increase in operative risk of stroke and death in
women compared to men. This highlights the need for
more sex-specific trials that will provide solid informa-
tion regarding the management of carotid disease in
women, define procedural indications for different risk
groups, and provide clear guidelines for the community.
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